Abstract: A machine is provided. The machine includes an engine, a work tool attached to the machine, and a work tool recognition system for the machine. The work tool recognition system includes a sensor associated with the work tool. The sensor is configured to generate a signal indicative of a weight of the work tool. The work tool recognition system includes a controller coupled to the sensor. The controller is configured to receive the signal indicative of the weight of the work tool. The controller is configured to monitor the weight of the work tool along a predefined path. The controller is configured to compare the monitored and the received weights associated with the work tool with a predefined dataset. The controller is configured to identify a type of the work tool based on the comparison.

Abstract: Disclosed are bladder cancer protein biomarkers, methods of determining whether a patient suffers from or shows recurrence of bladder cancer or early stage bladder cancer, or late stage bladder cancer using the bladder cancer protein biomarkers, a detection system, and kits thereof. Said bladder cancer biomarkers comprise at least one of Coronin-IA, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.

Abstract: A machine is provided. The machine includes an engine, a work tool attached to the machine, and a work tool recognition system for the machine. The work tool recognition system includes a sensor associated with the work tool. The sensor is configured to generate a signal indicative of a weight of the work tool. The work tool recognition system includes a controller coupled to the sensor. The controller is configured to receive the signal indicative of the weight of the work tool. The controller is configured to monitor the weight of the work tool along a predefined path. The controller is configured to compare the monitored and the received weights associated with the work tool with a predefined dataset. The controller is configured to identify a type of the work tool based on the comparison.

Abstract: The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Abstract: In a first aspect the present invention is directed to a method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient. It also refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC). The present invention also refers to a method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment.

Abstract: Disclosed are bladder cancer protein biomarkers, methods of determining whether a patient suffers from or shows recurrence of bladder cancer or early stage bladder cancer, or late stage bladder cancer using the bladder cancer protein biomarkers, a detection system, and kits thereof. Said bladder cancer biomarkers comprise at least one of Coronin-IA, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.

Abstract: The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Abstract: The method of sub-classifying breast cancer tumors profiles the expression of the Raf kinase inhibitor protein (RKIP) from a tissue sample from a cancerous primary breast tumor. The RKIP expression is profiled using its mRNA or by immunohistochemical protein quantifying methods in order to detect the level of RKIP in the breast cancer tissue sample. Based upon the RKIP expression profile, a sub-classification of cancer type may then be assigned. An RKIP expression of approximately 10.31 indicates basal carcinoma, an RKIP expression of approximately 10.04 indicates Claudin-low carcinoma, an RKIP expression of approximately 10.47 indicates Luminal-A carcinoma, an RKIP expression of approximately 10.44 indicates Luminal-B carcinoma, an RKIP expression of approximately 10.25 indicates HER2+ carcinoma, an RKIP expression of approximately 10.43 indicates ER+ carcinoma, and an RKIP expression of approximately 10.30 indicates ER? carcinoma.

Abstract: A method of identifying inhibitors of epithelial-mesenchymal transition (EMT). The method may comprise comparing different sets of image data obtained from one or more cell colonies before (T1) and after (T2) exposure to a possible inhibitor of epithelial-mesenchymal transition. The method may further comprise measuring the cell number and a spreading coefficient value in the one or more cell colonies for determining cell count ratio (CCR) and normalized cell dispersion ratio (CDR) for the one or more colonies. The possible inhibitor may then be identified to be an inhibitor of EMT if the determined CCR and CDR indicates that the possible inhibitor i) does not or marginally inhibit growth and inhibits EMT, or ii) inhibits growth and inhibits cell dispersion and optionally inhibits also EMT, or iii) is cytotoxic and inhibits cell dispersion and optionally inhibits also EMT.

Abstract: In a first aspect the present invention is directed to a method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient. It also refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC). The present invention also refers to a method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment.